Novartis, the maker of the drug Gilenya (fingolimod), a once-daily oral capsule taken for multiple sclerosis, has added stronger warnings to labels and prescription information about the drug’s possible heart risks, according to a company statement.
Source: http://www.webmd.com/multiple-sclerosis/news/20120420/new-warnings-for-ms-drug-gilenya-after-fda-review?src=RSS_PUBLIC
Walking The Dead Walking News Walking TV Walking Magazine Walking Medical
No comments:
Post a Comment